Holen Sie sich die Stockscreener-App
1.62
3.57%
-0.06
Handel nachbörslich:
1.62
60 Degrees Pharmaceuticals Inc Aktie (SXTP) Neueste Nachrichten
Enterprise value to EBIT forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
60 Degrees Pharmaceuticals, Inc. Warranton 60 Degrees Ph Financial Disclosures & SEC Filings - TradingView
SXTPW | 60 Degrees Pharmaceuticals, Inc. Executive Compensation - Quiver Quantitative
Equity plan hike and reverse split up for 60 Degrees (SXTP) shareholder vote - Stock Titan
60 Degrees Pharma babesiosis study clears safety review By Investing.com - Investing.com Nigeria
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue - Yahoo Finance Singapore
SXTP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SXTP Forecast — Price Target — Prediction for 2027 - TradingView
60 Degrees Pharmaceuticals, Inc. Actuals & Estimates (BOATS:SXTP) - TradingView
60 Degrees Pharmaceuticals Inc (SXTP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Price to book forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTPW - TradingView
Price to sales forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTPW - TradingView
Enterprise value to EBITDA forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTPW - TradingView
Enterprise value to EBIT forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTPW - TradingView
Enterprise value to revenue forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTPW - TradingView
60 Degrees Pharmaceuticals Inc (SXTP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Number of shareholders of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTPW - TradingView
SXTP News | 60 DEGREES PHARMA INC (NASDAQ:SXTP) - ChartMill
60 Degrees Pharmaceuticals Inc (SXTP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Institutional Confidence - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
60 Degrees Pharmaceuticals Inc - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Institutional Confidence - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Valuation: PE, PB & Fair Value Analysis - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Top Executive Makes Bold Move With Fresh Buy in Pharma Stock - TipRanks
Insider Buying: Geoffrey Dow Acquires Additional Shares of 60 De - GuruFocus
60 degrees pharmaceuticals CEO buys $10,131 in stock By Investing.com - Investing.com South Africa
60 degrees pharmaceuticals CEO buys $10,131 in stock - Investing.com
Insider Purchase: President and CEO of $SXTP Buys 7,350 Shares - Moomoo
CEO Geoffrey Dow adds 7,350 SXTP shares in open-market buy - Stock Titan
60 Degrees Pharmaceuticals Licenses Patent to Produce Australian Chestnut Extract - marketscreener.com
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - The Manila Times
Australian chestnut tree targeted for U.S. supplements in 60 Degrees Pharma deal - Stock Titan
60 Degrees Pharmaceuticals (SXTP) proposes 800K-share equity refresh, reverse split - Stock Titan
60 Degrees details tafenoquine priority review voucher strategy - The Globe and Mail
According to a document submitted to the U.S. Securities and Exchange Commission, the biopharmaceutical company 60 Degrees Pharmaceuticals, Inc. may submit a New Drug Application for its drug tafenoquine to the U.S. Food and Drug Administration bef - Bitget
60 Degrees Pharmaceuticals to seek Priority Review Voucher if tafenoquine trial supports NDA - TradingView
60 Degrees Pharmaceuticals (SXTP) details potential NDA and FDA voucher path - Stock Titan
60 Degrees Pharmaceuticals Q1 2026 Earnings: EPS Falls Sharply Short of Estimates as Development Costs MountDebt Analysis Report - The Legal Advocate
SXTP Q1 2026 Earnings: Significant EPS Miss as Company Continues Pre-Revenue PhaseROE Trend Analysis - The Legal Advocate
60 Degrees Pharm 1Q Rev $162,000 >SXTP - Moomoo
60 Degrees Pharmaceuticals (SXTP) Slips 6% as Shares Test Key SupportNew Highs New Lows - newsline.com
SXTP60 Degrees Pharmaceuticals Inc Stock Price and Quote - Finviz
60 Degrees Pharmaceuticals enrolls first patient in babesiosis trial - Investing.com
60 Degrees Pharmaceuticals enrolls first patient in babesiosis trial By Investing.com - Investing.com Canada
60 Degrees Pharmaceuticals Announces Early Enrollment of - GlobeNewswire
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis - Yahoo Finance
60 Degrees Pharmaceuticals Inc. (SXTP) Q1 2026 Earnings: EPS Misses Estimates, No Revenue YetFree Cash Flow Trends - The Legal Advocate
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):